826 abstracts found.



Results filter

High dose interleukin-2 can produce a very high rate of response in appropriately selected patients with metastatic renal cancer both in treatment naïve and patients pre-treated with sunitinib

Year:

Session type:

Robert Hawkins1, Alaaeldin Shablak1, Kanwal Sikand2, Jonathan Shanks1, Fiona Thistlethwaite1, Andrea Spencer-Shaw2
1University of Manchester and Christie Hospital, Manchester, United Kingdom,2The Christie Hospital, Manchester, United Kingdom

Targeting microRNA to induce cell death in Medulloblastoma

Year:

Session type:

Yuen Ngan Fan1, Daniel Meley1, Dave G Spiller1, Mike RH White1, Barry Pizer2, Violaine See1
1University of Liverpool, Liverpool, United Kingdom,2Alder Hey Hospital, Liverpool, United Kingdom

Pim kinases are essential for survival of Myc-induced lymphoma cells in vitro

Year:

Session type:

Linus Plym Forshell1, Tacha Zi Plym Forshell1, Jonas Nilsson1
1Department of Molecular Biology, Umeå, Sweden,2Department of Molecular Biology, Umeå, Sweden,3Department of Molecular Biology, Umeå, Sweden

Repression of 4F2hc impairs tumorigenicity

Year:

Session type:

Angélica Santiago-Gómez1, Javier Turnay1, Emilio Lecona1, Nieves Olmo1, Hans Burghardt2, Manuel Palacín2, Mª Antonia Lizarbe1
1Dept. Biochemistry and Molecular Biology I, Faculty of Chemistry, Complutense University of Madrid, Madrid, Spain,2Institute for Research in Biomedicine (IRB), Barcelona, Spain

Phase II Study of Single Agent Capecitabine in the Treatment of Metastatic Neuroendocrine Tumours

Year:

Session type:

Felicity Murphy1, Louise Medley1, Armand Morel1, David Farrugia2, Nicholas Reed3, Joanne Davies1, Oksana Kirichek1, Rajesh Thakker4, Denis Talbot1
1Department of Medical Oncology, University of Oxford, Oxford, United Kingdom,2Gloucestershire Hospital NHS Foundation Trust, Cheltenham General Hospital, Cheltenham, United Kingdom,3Beatson Oncology Centre, Western Infirmary, Glasgow, United Kingdom,4Oxford Centre for Diabetes, Endocrinology & Metabolism, Oxford, United Kingdom

Burden on primary caregivers of individuals with pancreatic cancer: results from the all-Ireland PanCAM study

Year:

Session type:

Damian O'Driscoll1, Michael O'Rorke2, Linda O'Keeffe1, Kevin Conlon3, Liam Murray2, Linda Sharp1
1National Cancer Registry Ireland, Cork, Ireland,2Queens University, Belfast, United Kingdom,3Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, Ireland

Investigating the role of lysyl oxidase (LOX) in renal cell carcinoma development

Year:

Session type:

Abdul Karim Fallah1, Qiuyu Wang1, John Gaffney1, Pat Kumar1, Shant Kumar1, Mark Slevin1
1Manchester Metropolitan University, Manchester, United Kingdom

Decreased expression of high molecular weight Tropomyosins in Squamous Cell Carcinoma of Esophagus (SCCE) 

Year:

Session type:

Maryam Zare1, Ferdous Rastgar Jazii1, Zahra- Soheila Soheili1
1Biochemistry department, National Institute of Genetic Engineering & Biotechnology (NIGEB), Tehran, Iran, Islamic Republic of

3D tumour models for the assessment of tumour micro-environment targeted therapies

Year:

Session type:

David Onion1, Richard Argent1, Rajendra Kumari1, Amy Axel2, Brett Hall2, Sue Watson1
1Ex Vivo Cancer Pharmacology Centre of Excellence, Division Of Pre-Clinical Oncology, University of Nottingham, Nottingham, United Kingdom,2OthoBiotech, Oncology Research & Development, Beerse, Belgium

CDKI-83?a novel CDK9 inhibitor as a potent anti-tumour agent

Year:

Session type:

Shenhua Shi1, Frankie Lam1, Xiangrui Liu1, Shudong Wang1
1University of Nottingham, Nottingham, United Kingdom

Syndecan-1 regulates mesenchymal tumour cell proliferation, adhesion and migration

Year:

Session type:

Fang Zong1, Eleni Fthenou2, Filip Mundt1, Péter Hollósi3, Ilona Kovalszky3, László Szilák3, Georgios Tzanakakis2, Anders Hjerpe1, Katalin Dobra1
1Karolinska Institute, Stockholm, Sweden,2University of Crete, Heraklion, Greece,3Semmelweis University, Budapest, Hungary

Combination therapy with an Aurora B kinase inhibitor AZD1152 and AraC, shows enhanced tumouricidal activity in a preclinical model of acute myeloid leukaemia (AML)

Year:

Session type:

Rajesh Odedra1, Robert W. Wilkinson1, Sarah V. Holt2, John R. Foster1, Elizabeth Anderson1
1AstraZeneca, Alderley Park, United Kingdom,2Paterson Institute of Cancer Research, Manchester, United Kingdom

An Application of Zinc Finger Nuclease Technology to Create Knockout Cancer Lines

Year:

Session type:

Suzanne Hibbs1, Gregory Wemhoff1, Gary Davis1
1Sigma Aldrich, Saint Louis, MO, United States

MGMT methylation is strongly associated with and may precede IDH1/IDH2 mutations in adult astrocytic and oligodendroglial tumours

Year:

Session type:

Shani Mulholland1, Deborah S Malley1, Rifat Hamoudi1, Sylvia Kocialkowski1, Danita Pearson1, V.Peter Collins1, Koichi Ichimura1
1Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom

P-cadherin identifies cells with stem-like properties in basal-like breast cancer

Year:

Session type:

Andre F Vieira1, Sara Ricardo1, Matthew Ablett2, Raquel Seruca3, Fernando Schmitt3, Robert B Clarke2, Joana Paredes1
1Institute of Molecular Pathology and Immunology of the University of Porto, Porto, Portugal,2Paterson Institute for Cancer Research, Manchester, United Kingdom,3Medical Faculty of the University of Porto, Porto, Portugal

The relationships between the systemic inflammatory response, plasma and red cell B vitamins concentrations and survival in patients with colorectal cancer

Year:

Session type:

Elaine Leung1, Campbell Roxburgh1, Dinesh Talwar2, Dennis O'Reilly2, Ruth McKee1, Paul Horgan1, Donald McMillan1
1University Department of Surgery, Glasgow, United Kingdom,2University Department of Biochemistry, Glasgow, United Kingdom

P14ARF-p53 induced senescence revisited: protector or precursor of latent breast cancer?

Year:

Session type:

Eileen McGowan1, Daniel Yagoub2, Nikki Alling3
1Centenary, Sydney, Australia,2University of Sydney, Sydney, Australia,3Royal Prince Alfred Hospital, Sydney, Australia,4Garvan Institute of Medical Research, Sydney, Australia

The role of CYP2C40 and CYP2C55 in colon cancer

Year:

Session type:

Michael Albert1, Andrew Bennett1
1Nottingham University School of Biomedical Sciences, Nottingham, United Kingdom

Tetrahydrobiopterin synthesis in cancer-associated fibroblasts promotes tumour angiogenesis and progression

Year:

Session type:

Xin Zeng1, Liye Chen1, Michael Presz1, Simon Briggs1, Russell leek1, Gillies McKenna1, Adrian Harris1, Shijie Cai1
1University of Oxford, Oxford, United Kingdom

Structural characterisation of human mitotic kinesin – KIF15

Year:

Session type:

Marta Kozlowska1, Venkatasubramanian Ulaganathan1, Frank Kozielski1
1The Beatson Institute for Cancer Research, Glasgow, United Kingdom

Gene expression profile induced by genotoxic and non-genotoxic carcinogens in the rat kidney cells

Year:

Session type:

Kate Bloch1, Edward A Lock1, Andrew Evans1
1Liverpool John Moores University, Liverpool, United Kingdom

Piwil2 expression selects for known stem-cell and cancer stem-cell markers in LNCaP prostate cancer cell line

Year:

Session type:

Deepali Pal1, Craig Robson1, Stuart Williamson1, Karim Nayernia2, Hamid Reza Soleimanpour-Lichaei2, Rakesh Heer1
1Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom,2North East England Stem Cell Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

miR-224 is marker of poor prognosis in breast cancer.

Year:

Session type:

Sharon McGee1, Laoighse Mulrane1, Donal Brennan1, Susan McDonnell1, Karin Jirstrom2, Darran O'Connor1, William Gallagher1
1University College Dublin, Dublin, Ireland,2Lund University, Lund, Sweden

Cadmium inhibits gelatinolytic activities of MMP2 and MMP9: another possible mechanism of cadmium-induced carcinogenesis

Year:

Session type:

Livia Lacorte1, Carolina Sarobo1, Elaine Porto1, Luis Justulin Jr1, Flavia Delella1, Sergio Felisbino1
1Sao Paulo State University UNESP, Botucatu, SP, Brazil

Finasteride interfere with MMP2 and MMP9 expression profile on human prostate cancer PC-3 cell line

Year:

Session type:

Andrei Moroz1, Flavia Delella1, Sergio Santos1, Jaqueline Rinaldi1, Andrelson Rinaldi4, Elenice Deffune2, Hernandes Carvalho3, Sergio Felisbino1
1Biosciences Institute, Department of Morphology - Sao Paulo State University (UNESP), Botucatu, SP, Brazil,2Blood Transfusion Center, Cell Engineering Laboratory - Sao Paulo State University (UNESP), Botucatu, SP, Brazil,3Biology Institute, Department of Cell Biology, Campinas State University (UNICAMP), Campinas, SP, Brazil,4Grande Dourado Federal University, Exact Sciences and Technology School (UFGD), Grande Dourado, MS, Brazil

HER-2 expression has no adverse prognostic signficance in caucasian patients with gastro-oesophageal adenocarcinomas: Analysis of Brightfield double In Situ hybridisation (BDISH) for HER-2 gene amplification and immunohistochemistry for HER-2 protein expression

Year:

Session type:

Michelle Cunnell1, Alex Reecesmith2, Irshad Soomro3, Zia Chaudry3, Ian Ellis3, Simon Parsons2, Srinivasan Madhusudan1
1Academic Unit of Oncology, School of Molecular Medical Sciences, Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham University Hospitals, Nottingham, United Kingdom,2Department of Surgery, Nottingham University Hospitals, Nottingham, United Kingdom,3Department of Pathology, Nottingham University Hospitals, Nottingham, United Kingdom

Akt interacts with DNA-PKcs for optimal DNA damage repair

Year:

Session type:

Mahmoud Toulany1, H. Peter Rodemann1
1Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, Eberhard-Karls University Tuebingen, Tuebingen, Germany

Patient and public involvement in cancer research in the United Kingdom

Year:

Session type:

Thomas Haswell1
1NCRI Consumer Liaison Group, London, United Kingdom

In vivo pharmaceutical target screening using a lentiviral inducible-knockdown shRNA system

Year:

Session type:

Yinfei Yin1, Rajendra Kumari1, Sue Watson1, Brett Hall2, Martin Page2, Peter King2, Anna Grabowska1
1Ex Vivo Cancer Pharmacology Centre Of Excellence, Division Of Pre-Clinical Oncology, University Of Nottingham, Nottingham, United Kingdom,2OrthoBiotech, Oncology Research & Development, Beerse, Belgium

Information and its role: the experiences of people affected with laryngeal cancer

Year:

Session type:

Anne Taylor1, Sally Wyke1, Gill Hubbard1
1University of Dundee, Dundee, United Kingdom

Treatment patterns and outcomes in advanced melanoma in UK: a retrospective longitudinal survey (MELODY study)

Year:

Session type:

Mark Middleton1, Maria Marples1, Mark Harries1, John Wagstaff1, Angus Dalgleish1, Richard Osborne1, Anthony Maraveyas1, Steve Nicholson1, Neville Davidson1, Qing Wang1, Urmi Bapat1, Paul Lorigan1
1Oxford NIHR Biomedical Research Centre, Oxford, United Kingdom,2Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom,3St Thomas’ Hospital, London, United Kingdom,4Singleton Hospital, Swansea, United Kingdom,5St George’s Hospital, London, United Kingdom,6Dorset Cancer Centre, Poole, United Kingdom,7The Princess Royal Hospital, Hull, United Kingdom,8University Hospitals of Leicester, Leicester, United Kingdom,9Broomfield Hospital, Essex, United Kingdom,10Bristol-Myers Squibb Pharmaceuticals, Uxbridge, United Kingdom,11Bristol-Myers Squibb Pharmaceuticals, Uxbridge, United Kingdom

Risk stratification of cancer survivors: a quantitative method using clinical attendance patterns for colorectal, Hodgkin’s disease and multiple myeloma.

Year:

Session type:

Katie Harris1, Kimberley Edwards1, Ashley Woolmore2, James Wells2, Catherine Boyle3, Tom Farrell1, Haley Nai1, Eva Morris5, James Thomas5, David Forman4
1University of Leeds, Leeds, United Kingdom,2Monitor, London, United Kingdom,3Macmillan, London, United Kingdom,4IARC, Lyon, France,5NYRCIS, Leeds, United Kingdom

Exploring and prioritising the support needs of older carers of people with advanced cancer: a partnership approach to research

Year:

Session type:

Sheila Kennedy1, Jane Seymour1, Lydia Bird1, Karen Cox1
1University of Nottingham, Nottingham, United Kingdom

Establishment of a preclinical orthotopic model for human malignant bone disease in immunocompromised NSG mice using small animal PET, CT and MRI imaging

Year:

Session type:

Henrike K Knizia1, Mike A Batey1, Gilberto S Almeida1, Ian Wilson1, Ross J Maxwell1, Petra Dildey2, I Geoff Hide2, Chris M Bacon1, H Josef Vormoor1
1Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom,2Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

Dock4 is a Rac1 GEF downstream of VEGF signalling required for lumen formation in tumour blood vessels

Year:

Session type:

Sabu Abraham1, Tracey Harvey2, Margherita Scarcia2, Margaret Yeo1, Christopher Marshall1, Georgia Mavria2
1Institute of Cancer Research, London, United Kingdom,2Leeds Institute of Molecular Medicine, St James' University Hospital, Leeds, United Kingdom

Inhibition of Lsd1 Function Abrogates AML Leukaemia Stem Cell Self Renewal through Induction of Myeloid Differentiation

Year:

Session type:

William Harris1, Tim Somervaille1
1Paterson Institute for Cancer Research, Manchester, United Kingdom

“A functional shRNAi screen of phosphoinositide modulators in haematopoiesis and leukaemogenesis”

Year:

Session type:

Julian Blaser1, Tim Somervaille1, Nullin Divecha1
1Paterson Institute for Cancer Research, Manchester, United Kingdom

The use of the tumor 3-D spheroid model for screening for anticancer activity: a strategy for identification anticancer agents with activity on solid tumors

Year:

Session type:

Walid Fayad1, Rolf Larsson2, Stig Linder1, Mårten Fryknäs2
1Karolinska Institute, Stockholm, Sweden,2Uppsala University, Uppsala, Sweden

BRAF mutation confers TGF-? addiction

Year:

Session type:

John Ferguson1, Yvonne Fleming1, Gary Sibbett1, Lindsay Spender1, Norman Sharpless2, Michael Weller3, Margaret Frame4, Richard Marais5, Gareth Inman6
1The Beatson Institute for Cancer Research, Glasgow, United Kingdom,2The Lineberger Comprehensive cancer Center, Chapel Hill, NC, United States,3University Hospital Zurich, Zurich, Switzerland,4Edinburgh Cancer Centre, Edinburgh, United Kingdom,5Institute for Cancer Research, London, United Kingdom,6Biomedical Research Institute, Dundee, United Kingdom

Amplified and overexpressed genes in cancer (AOGIC)

Year:

Session type:

Daniel Brewer1, Thomas Santarius2, Janet Shipley1, Michael Stratton2, Colin Cooper1
1Institute of Cancer Research, Sutton, United Kingdom,2The Wellcome Trust Sanger Centre, Cambridge, United Kingdom

UK prostate cancer sample collection database (UKPCSCD)

Year:

Session type:

Daniel Brewer1, Rajeev Kumar4, Jen Tibbets4, Ian Giddings1, Sandra Edwards1, Hayley Whitaker3, Peter Maccallum3, Feddie Hamdy4, David Neal2, Colin Cooper1
1Institute of Cancer Research, Sutton, United Kingdom,2University of Cambridge, Cambridge, United Kingdom,3Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom,4University of Oxford, Oxford, United Kingdom

Epidemiology of breast cancer in Setif, Algeria

Year:

Session type:

Z. Zaidi1, F. Babouche2, D. Abdellouche3, A. Djema Djazia4, M. Abdoun1, M. Hamdi Cherif1
1Cancer registry of Setif- University Hospital of Setif, Setif, Algeria,2Private Office of Radiology, Health Direction of Setif, Setif, Algeria,3Department of Anatomopathology-University Hospital of Setif, Setif, Algeria,4Constantine Anti-cancer Center - University Hospital of Constantine, Constantine, Algeria

Restoration of paracrine signalling within the tumour microenvironment increases tumour growth and activation of c-Met

Year:

Session type:

Richard Argent1, Rajendra Kumari1, Phil Clarke1, David Onion1, Dileep Lobo2, Anna Grabowska1, Peter King3, Brett Hall3, Martin Page3, Sue Watson1
1Ex Vivo Cancer Pharmacology Centre Of Excellence, Division Of Pre-Clinical Oncology, University Of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom,2Division Of Gastrointestinal Surgery, Nottingham Digestive Diseases, Biomedical Research Unit, Nottingham University Hospitals, Queen's Medical Centre, Nottingham, United Kingdom,3OrthoBiotech, Oncology Research & Development, Beerse, Belgium

Trends in prostate cancer incidence in Setif, Algeria between 1986-2005

Year:

Session type:

Z. Zaidi1, F. Babouche2, D. Abdellouche3, A. Djema Djazia4, A. Mahnane1, M. Hamdi Cherif1
1Cancer registry of Setif- University Hospital of Setif, Setif, Algeria,2Private Office of Radiology, Health Direction of Setif, Setif, Algeria,3Department of Anatomopathology-University Hospital of Setif, Setif, Algeria,4Constantine Anti-Cancer Center - University hospital of Constantine, Constantine, Algeria

Polypyrimidine-tract-binding protein (PTB): a role in alternative splicing of the Fibroblast Growth Factor Receptor (FGFR) 2 gene.

Year:

Session type:

Raquel Duarte1, Pooja Seedhar1
1Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa,2Cancer Research UK, London, United Kingdom

Management of insomnia among cancer patients: A pilot study from cancer patients perspectives

Year:

Session type:

Maryam Farooqui1, Heryohana Jamulidin1
1University Technologi MARA, Pulau Pinang, Malaysia

The human tumour micro-environment modelled in in vitro biomatrices and applied to cancer drug discovery

Year:

Session type:

Teresa Coughlan1, Suzanne Underwood1, Phil Clarke1, Elizabeth Whelband1, Richard Argent1, Anna Grabowska1, Snow Stolnik2, Brett Hall3, Rajendra Kumari1, Sue Watson1
1Division of Pre-Clinical Oncology, University of Nottingham, Queen's Medical Centre, Nottingham, United Kingdom,2School of Pharmacy, University Of Nottingham, Nottingham, United Kingdom,3OrthoBiotech, Oncology Research & Development, Beerse, Belgium

Biochemical and structural investigation of mutations in Eg5 that confer resistance to anti-mitotic drugs

Year:

Session type:

Sandeep Kumar Talapatra1, Venkatasubramanian Ulaganathan1, Frank Kozielski1
1The Beatson Institute for Cancer Research, Glasgow, Scotland, United Kingdom

Comparison of PERCIST to RECIST response assessment for patients recieving chemo-radiation plus nelfinavir for unresectable pancreatic cancer.

Year:

Session type:

Cynthia Eccles1, Katherine Vallis1, Thomas Brunner1
1Gray Institute for Radiation Oncology and Biology, Oxford, United Kingdom

Trastuzumab-related cardiac toxicity in patients with Her-2 positive early breast cancer: Experience from a regional cancer centre

Year:

Session type:

Ravi Dandamudi1, D A Jones1, christopher Poole1, r j Grieve1
1university hospitals coventry and warwickshire NHS trust, coventry, United Kingdom